We are live on
!
Find out more
Frazier Life Sciences Management Portfolio holdings
AUM
$4.59B
Turnover
20.45%
1-Year Est. Return
237.58%
This Fund
S&P 500
This Quarter
Est. Return
+18.89%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
+$357M
(+17%)
Cap. Flow
+$201M
Cap. Flow
% of AUM
8.05%
Top 10 Holdings %
Top 10 Hldgs %
59.89%
Holding
57
New
8
Increased
13
Reduced
5
Closed
4
Avg Time Held
1.3
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MBX Biosciences
MBX
|
+$137M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$18M |
| 3 |
Oruka Therapeutics
ORKA
|
+$16.6M |
| 4 |
Alkermes
ALKS
|
+$15.4M |
| 5 |
Lexeo Therapeutics
LXEO
|
+$14.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edgewise Therapeutics
EWTX
|
+$17.9M |
| 2 |
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$16.1M |
| 3 |
Vaxcyte
PCVX
|
+$14.4M |
| 4 |
Applied Therapeutics
APLT
|
+$10.7M |
| 5 |
PepGen
PEPG
|
+$9.47M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.86% |
| 2 | Miscellaneous | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Mirum Pharmaceuticals
MIRM
$5.19B
| $256M | 10.27% |
6,570,392
+75,000
| +1% | +$2.99M |
2022 Q1
10 quarters
|
|
2
NewAmsterdam Pharma
NAMS
$2.39B
| $213M | 8.55% |
12,855,194
+628,251
| +5% | +$10.9M |
2022 Q4
7 quarters
|
|
3
Phathom Pharmaceuticals
PHAT
$599M
| $183M | 7.33% |
10,109,279
| – | – |
2022 Q1
10 quarters
|
|
4
Krystal Biotech
KRYS
$9.79B
| $180M | 7.21% |
988,460
| – | – |
2022 Q1
10 quarters
|
|
|
5
MBX Biosciences
MBX
$2.35B
| $155M | 6.23% |
+5,985,347
| New | +$137M |
2024 Q3
0 quarters
|
|
6
Rhythm Pharmaceuticals
RYTM
$5.97B
| $127M | 5.08% |
2,416,952
+45,648
| +2% | +$2.19M |
2022 Q3
8 quarters
|
|
|
7
Vaxcyte
PCVX
$10.6B
| $100M | 4.03% |
879,405
-160,000
| -15% | -$14.4M |
2022 Q1
10 quarters
|
|
|
VRNA
8
DELISTED
Verona Pharma
VRNA
| $97.4M | 3.9% |
3,383,950
+69,601
| +2% | +$1.71M |
2022 Q3
8 quarters
|
|
9
BridgeBio Pharma
BBIO
$12.7B
| $95.7M | 3.84% |
3,760,457
+127,853
| +4% | +$3.36M |
2023 Q1
6 quarters
|
|
10
Disc Medicine
IRON
$2.14B
| $86.2M | 3.46% |
1,754,834
| – | – |
2023 Q2
5 quarters
|
|
11
Arcutis Biotherapeutics
ARQT
$3.32B
| $81.7M | 3.27% |
8,785,284
| – | – |
2022 Q1
10 quarters
|
|
|
12
Edgewise Therapeutics
EWTX
$4.02B
| $75.6M | 3.03% |
2,832,867
-898,200
| -24% | -$17.9M |
2023 Q1
6 quarters
|
|
13
AnaptysBio
ANAB
$1.4B
| $74M | 2.97% |
2,209,189
+43,598
| +2% | +$1.49M |
2022 Q1
10 quarters
|
|
14
Erasca
ERAS
$5.14B
| $52.9M | 2.12% |
19,391,687
+3,175,471
| +20% | +$8.94M |
2024 Q2
1 quarter
|
|
15
Tarsus Pharmaceuticals
TARS
$3.38B
| $52.2M | 2.09% |
1,587,527
| – | – |
2022 Q1
10 quarters
|
|
16
Agios Pharmaceuticals
AGIO
$1.85B
| $46.4M | 1.86% |
1,044,154
+172,180
| +20% | +$7.82M |
2023 Q3
4 quarters
|
|
17
Revolution Medicines
RVMD
$41.5B
| $45.2M | 1.81% |
997,455
| – | – |
2023 Q1
6 quarters
|
|
18
DELISTED
Soleno Therapeutics
SLNO
| $44.2M | 1.77% |
875,667
| – | – |
2023 Q3
4 quarters
|
|
19
DELISTED
KalVista Pharmaceuticals
KALV
| $42.7M | 1.71% |
3,687,867
| – | – |
2022 Q1
10 quarters
|
|
20
Oric Pharmaceuticals
ORIC
$1.2B
| $42.5M | 1.7% |
4,142,855
| – | – |
2023 Q2
5 quarters
|
|
21
Ultragenyx Pharmaceutical
RARE
$1.47B
| $35.2M | 1.41% |
633,715
+208,715
| +49% | +$10.6M |
2024 Q2
1 quarter
|
|
22
Savara
SVRA
$978M
| $34.6M | 1.39% |
8,157,385
| – | – |
2023 Q3
4 quarters
|
|
23
CG Oncology
CGON
$5.48B
| $29.1M | 1.16% |
770,000
| – | – |
2024 Q1
2 quarters
|
|
24
Rocket Pharmaceuticals
RCKT
$243M
| $27.4M | 1.1% |
1,485,630
-75,600
| -5% | -$1.55M |
2023 Q3
4 quarters
|
|
25
Trevi Therapeutics
TRVI
$1.72B
| $24.7M | 0.99% |
7,381,090
| – | – |
2022 Q2
9 quarters
|
|
Similar funds
BWA
TYCC
Frazier Life Sciences Management's Q3 2024 Portfolio in Review
As of Q3 2024, Frazier Life Sciences Management held 57 positions worth $2.5B, up 17% from $2.14B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Frazier Life Sciences Management deployed $201M of net new capital in Q3 2024, opening 8 new positions and adding to 13 existing holdings. Its largest new stake was MBX Biosciences: 5,985,347 shares worth $155M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Edgewise Therapeutics, an estimated $17.9M trimmed.
- Frazier Life Sciences Management's largest Q3 2024 buy was MBX Biosciences: 5,985,347 shares worth $155M.
- Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q3 2024, an estimated $10.9M increase.
- Frazier Life Sciences Management's biggest Q3 2024 reduction was Edgewise Therapeutics, cutting an estimated $17.9M.
- Frazier Life Sciences Management fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $16.1M.
- Frazier Life Sciences Management's ten largest holdings make up 60% of its $2.5B portfolio in Q3 2024.
- Frazier Life Sciences Management opened 8 new positions and closed 4 in Q3 2024.
- Frazier Life Sciences Management's portfolio value rose 17% quarter-over-quarter to $2.5B.
Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.